Nature's Toolbox (NTx), a life sciences company developing next-generation platforms for RNA and protein manufacturing, today announced the founding of its Scientific Advisory Board (SAB) with ...

The latest HPRA inspection in February 2025 was highly successful-both QC licences were renewed, and viral vector manufacturing was added to the MIA (IMP) licence. This means the Shannon site can ...

OS Therapies, Inc. , a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has been awarded a presentation slot at ...

Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25; Deep and durable responses maintained over 12 months in ...

Achieves alignment with U.S. Food and Drug Administration (FDA) on regulatory path for potential accelerated approval of iopofosine I 131 as a ...

Reports revenue $38.9M, consensus $39.74M. “Following a year marked by tremendous progress, we remain committed to advancing our pipeline of ...

Arcutis is a rare topical dermatology player with accelerating launch metrics and continued growth. Read more about the ...

Q4 2024 Earnings Call Transcript March 11, 2025 Zevra Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0 ...

Pediatric kidney disease are rarely talked about, yet they can have lifelong consequences. Unlike adults, who have clear ...

RedHill Biopharma (RDHL) announced plans to advance its groundbreaking late-stage program for Crohn’s disease, or CD, with initiation of an ...

FY 2024 net revenue of $23.6 million, driven by net revenue of $12.0 million during fourth quarter of 2024Entered into asset purchase agreement ...